Incruse Ellipta: New once-daily inhaled antimuscarinic for COPD

Incruse Ellipta (umeclidinium) is a once-daily long-acting anticholinergic bronchodilator used to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults

by
NICE recommends adding a LAMA to a regimen containing an inhaled long-acting beta agonist and a corticosteroid in patients who remain breathless or have exacerbations despite their existing treatment.
NICE recommends adding a LAMA to a regimen containing an inhaled long-acting beta agonist and a corticosteroid in patients who remain breathless or have exacerbations despite their existing treatment.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package